TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00935350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: 0 grams of PGX
Study: NCT02975999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Study: NCT00085982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
Study: NCT03514511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S
Study: NCT03961659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT03382457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Repair
Description: Repair of the tricuspid valve through a transcatheter approach
Study: NCT02458859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO (single use portable negative pressure wound therapy)
Description: Single use portable negative pressure wound therapy
Study: NCT03514511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo
Study: NCT04215146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
Study: NCT03514511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559 placebo
Description: LEO 138559 placebo
Study: NCT04215146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
Study: NCT02211768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI, FDG-PET/CT scans
Description: Standard of care to be obtained as part of the study

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI, FDG-PET/CT scans
Description: Standard of care to be obtained as part of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FLT-PET/CT scans
Description: FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
Study: NCT04019106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in bovine lipid extract surfactant (BLES)
Description: Budesonide in bovine lipid extract surfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in bovine lipid extract surfactant (BLES)
Description: Budesonide in bovine lipid extract surfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in bovine lipid extract surfactant (BLES)
Description: Budesonide in bovine lipid extract surfactant
Study: NCT02776462

Intervention type: DEVICE
Intervention: EyeBox CNS
Study: NCT03324334

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid antibodies
Description: Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid antibodies
Description: Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid sonography
Description: Thyroid sonography to detect anatomical changes in thyroid

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid sonography
Description: Thyroid sonography to detect anatomical changes in thyroid
Study: NCT03053986

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple polyphenols
Description: 1 tablet per day at evening before sleeping

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day at evening before sleeping
Study: NCT01294306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study: NCT04215146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
Study: NCT03638726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine sulfate and epinephrine
Description: Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.

Intervention type: DRUG
Group type: OTHER
Intervention: Topical cyclopentolate and phenylephrine
Description: Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
Study: NCT02851745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02870010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples (5 ml) will be taken
Description: blood samples (5 ml) will be taken
Study: NCT02370797

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Fraction IOeRT
Description: A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
Study: NCT03660826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study: NCT00053040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cintredekin besudotox
Description: IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
Study: NCT03660826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo Echo
Study: NCT01294306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03660826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT03187223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
Study: NCT02870010

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
Study: NCT02803424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume controlled ventilation
Description: During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autoflow-volume controlled ventilation
Description: After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
Study: NCT04007653

Intervention type: OTHER
Intervention: Observation
Description: No intervention

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT04785755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral standard diuretics therapy
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral standard diuretics therapy
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral standard diuretics therapy
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral standard diuretics therapy
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
Study: NCT04085458

Intervention type: DRUG
Group type: OTHER
Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027)
Description: The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
Study: NCT02554149

Intervention type: RADIATION
Intervention: Radiological measurement of femoral stem version
Description: particular radiographs( lateral decubitus view) and CT scans
Study: NCT06075966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-fusion group
Description: Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fusion group
Description: Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fusion group
Description: Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fusion group
Description: Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University